The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Using ctDNA to inform treatment strategies in colorectal cancer
Emerik Osterlund, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the impact of circulating tumor DNA (ctDNA) results on treatment decisions in colorectal cancer, noting that a negative result may have encouraged some patients to forgo adjuvant therapy, while a positive result may have led to escalated treatment, although most patients received standard treatment. The results from the INTERCEPT program may overall have had more of an impact in the context of another trial enrolling patients in the same setting. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Not that much within the INTERCEPT program. Of course, some in the real world might have. If there were a low risk to begin with a ctDNA negative, that probably encouraged them to not pursue adjuvant therapy. And some, if positive, you might have escalated it a bit, but it’s of course all off protocol and I would say most of the patients still sort of received what they would have just been received regardless and then at the same time we’d also have another trial enrolling patients in this setting so I would say it’s more maybe impactful in that setting with the other trial...
Not that much within the INTERCEPT program. Of course, some in the real world might have. If there were a low risk to begin with a ctDNA negative, that probably encouraged them to not pursue adjuvant therapy. And some, if positive, you might have escalated it a bit, but it’s of course all off protocol and I would say most of the patients still sort of received what they would have just been received regardless and then at the same time we’d also have another trial enrolling patients in this setting so I would say it’s more maybe impactful in that setting with the other trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
